NCT06710080View on ClinicalTrials.gov

Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
InflammationCommunity Acquired Pneumonia (CAP)Inflammation Plaque, Atherosclerotic
Interventions
DRUG

Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

Participants randomized to the treatment arm will receive Vascepa 1000mg twice a day for 6 months.

DRUG

Placebo

Placebo twice daily

Trial Locations (1)

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
lead

Ottawa Heart Institute Research Corporation

OTHER